Méndez-Sánchez N, Chávez-Tapia NC, Uribe M

Idioma: Español
Referencias bibliográficas: 49
Paginas: 67-72
Archivo PDF: 194.28 Kb.

RESUMEN

La obesidad es uno de los principales factores asociados al desarrollo de esteatohepatitis no alcohólica. Debido principalmente a resistencia periférica a la acción de la insulina, incremento del flujo portal de triglicéridos, y la producción de citocinas inflamatorias que afectan de forma deletérea a los hepatocitos. Estas alteraciones originan eventos fisiopatológicos similares a los observados en la hepatitis alcohólica, sin embargo no existe el antecedente de uso o abuso de esta sustancia. La esteatohepatitis no alcohólica tiene gran importancia debido a que la mayoría de los casos diagnosticados como cirrosis criptogénica actualmente se atribuyen a esta enfermedad. A pesar de los avances en el entendimiento de sus aspectos fisiopatológicos, no existe un tratamiento más eficaz que la disminución de peso (combinación de dieta y ejercicio). En este artículo revisamos los aspectos más importantes de la esteatohepatitis no alcohólica y su relación con la obesidad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tate DF, Jackvony EH, Wing RR. Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA 2003;289(14):1833-6.

2. Hu FB, Li TY, Colditz GA, Willett WC, Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003;289(14):1785-91.

3. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-9.

4. Méndez-Sánchez N, Sánchez-Castillo CP, Villar AR, et al. Relación entre sobrepeso y obesidad con mortalidad por cirrosis hepática en México. Rev Gastr Mex 2003;68(Supl 3):176.

5. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161(13):1581-6.

6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-31.

7. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55(7):434-8.

8. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124(1):71-9.

9. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122(6):1649-57.

10. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21(1):17-26.

11. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84(5):1513-7.

12. Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002;97(7):1796-801.

13. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35(6):1485-93.

14. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37(4):909-16.

15. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107(4):1103-9.

16. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003;88(6):2534-40.

17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486-97.

18. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87(7):3023-8.

19. Busetto L, Tregnaghi A, De Marchi F, et al. Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 2002;10(5):408-11.

20. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999;274(9):5692-700.

21. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001;34(4 Pt 1):694-706.

22. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120(5):1183-92.

23. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94(6):2557-62.

24. Méndez-Sánchez N, Chávez-Tapia NC, Uribe M. [An update on non-alcoholic fatty liver disease]. Rev Invest Clin 2004;56(1):72-82 (en espańol).

25. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37(5):1202-19.

26. Méndez-Sánchez N, Motola-Kuba D, Bahena-Aponte J, Chávez-Tapia N, Pichardo-Bahena R, Uribe M. Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. Ann Hepatol 2003;2(4):183-5.

27. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35(2):195-9.

28. García-Monzón C, Martín-Pérez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33(5):716-24.

29. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003;143(4):500-5.

30. Longo R, Ricci C, Masutti F, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993;28(4):297-302.

31. Jones NL, Killian KJ. Exercise limitation in health and disease. N Engl J Med 2000;343(9):632-41.

32. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970;282(15):829-34.

33. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220(1):83-8.

34. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12(2):224-9.

35. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967;12(2):198-208.

36. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99(5):1408-13.

37. Méndez-Sánchez N, González V, Pichardo-Bahena R, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Hepatology 2002;36:412A.

38. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sci 1987;32(4):441-5.

39. Saksena S, Johnson J, Ouiff SP, Elias E. Diet and exercise: important first steps in therapy of NASH. Hepatology 1999;30:436A.

40. Vajro P, Fontanell A, Perna C, Orso G, Tudesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving alter weight reduction in obese children. J Pediatr 1994;125:239-41.

41. Guma G, Viola L, Thomé M, Galdame O, Alvarez E. Ursodesoxycholic acid in the treatment of nonalcoholic steatohepatitis results of a prospective clinical controlled trial. Hepatology 1997;26:387A.

42. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996;403:607-13.

43. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27(1):103-7.

44. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother 2003;4(5):611-23.

45. Angulo P. Treatment of nonalcoholic fatty liver disease. Ann Hepatol 2002;1:12-9.

46. Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Arch Intern Med 1998;158(17):1855-67.

47. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptindeficient mice. Nat Med 2000;6(9):998-1003.

48. Nairs S, Diehl AM, Perrillo R. Metformin in nonalcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report. Gastroenterology 2002;122:4.

49. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23(6):1464-7.